Baird analyst David Rescott raised the firm’s price target on iRhythm (IRTC) to $220 from $180 and keeps an Outperform rating on the shares. The firm updated its model afterlaying out its bull caseon 2027 estimates. The shares remain a top small-midcap idea.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm price target raised to $205 from $183 at Citi
- iRhythm price target raised to $193 from $170 at Canaccord
- CoreWeave upgraded, Lululemon downgraded: Wall Street’s top analyst calls
- iRhythm initiated with an In Line at Evercore ISI
- Irhythm Technologies: Strategic Market Expansion and Clinical Efficacy Drive Buy Rating